FDA Inspection 1215617 — Department of Defense - Army (Armed Services Blood Program)

Department of Defense - Army (Armed Services Blood Program) — FEI 3002964709

The FDA completed an inspection of Department of Defense - Army (Armed Services Blood Program) on August 23, 2023 in Landstuhl. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
August 23, 2023
Fiscal Year
2023
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Landstuhl (Germany)

Citations

IDCFRDescription
1220321 CFR 606.170(a)Adverse Reaction- Reports of Investigations